CPHI AMEX
China Pharma Holdings, Inc.
1W: -14.7%
1M: -24.1%
3M: -6.1%
YTD: -47.0%
1Y: -67.0%
3Y: -90.8%
5Y: -99.8%
$0.66
+0.00 (+0.61%)
Weekly Expected Move ±8.6%
$1
$1
$1
$1
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$5M
-35.4% ▼
5Y CAGR: -16.1%
Gross Profit
-$2M
-606.4% ▼
Operating Income
-$5M
-66.8% ▼
Net Income
-$5M
-53.8% ▼
EPS (Diluted)
$-0.27
+6.9% ▲
EBITDA
-$2M
-23383.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $11M | $10M | $8M | $7M | $5M |
| YoY Growth | -0.5% | -11.3% | -15.9% | -13.5% | -35.4% |
| Cost of Revenue | $9M | $9M | $9M | $7M | $7M |
| Gross Profit | $2M | $349K | -$494K | -$281K | -$2M |
| Gross Margin | 18.0% | 3.6% | -6.1% | -4.0% | -43.8% |
| R&D Expenses | $378K | $319K | $186K | $240K | $284K |
| SG&A Expenses | $4M | $3M | $3M | $2M | $2M |
| Operating Expenses | $5M | $3M | $3M | $2M | $3M |
| Operating Income | -$3M | -$3M | -$4M | -$3M | -$5M |
| Operating Margin | -23.7% | -29.7% | -43.8% | -39.2% | -101.3% |
| Interest Expense | $294K | $542K | $435K | $334K | $154K |
| Income Before Tax | -$3M | -$3M | -$4M | -$3M | -$5M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$3M | -$3M | -$4M | -$3M | -$5M |
| Net Margin | -26.4% | -35.3% | -49.0% | -43.9% | -104.6% |
| EPS (Diluted) | $-0.72 | $-0.85 | $-1.94 | $-0.29 | $-0.27 |
| EBITDA | $107K | $230K | -$838K | $8K | -$2M |
| Shares Outstanding | 5M | 5M | 5M | 11M | 17M |